Literature DB >> 2798648

The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics.

M Shepherd1, D Watt, I Falloon, N Smeeton.   

Abstract

Longitudinal studies of schizophrenia based on at least 70 subjects and a minimum five-year follow-up period are reviewed in respect of the requirements of adequate method. A cohort of 121, PSE-diagnosed, schizophrenic admissions from a defined population was identified. The sex-distribution of the subjects was almost equal. Forty per cent were first admissions; 65% of the men and 24% women were unmarried; the mean age of onset for men was 28.6 years, for women 33.2 years. Almost half (48%) were continuously employed (including house and child care) for 2 years prior to admissions. First rank symptoms of schizophrenia were present in 79% of the men and 86% of the women. Comprehensive, standardized assessments of clinical state and social function were made on discharge from hospital and at follow-up by home interview of patient and relative(s). Outcome was also assessed by duration and frequency of readmission and by duration of employment. First admissions were analysed separately from the whole cohort. There were 49 first admissions generating an incidence of 7.4 per 100,000 general population per annum. Sixty-nine per cent of men and 13% of women were unmarried. The mean age of admission for men was 30.8 years, women 40.3 years and the mean age of onset 30.7 and 38.6 respectively. After 5 years first rank symptoms were present in 46% of the males and 35% of the females. The proportion showing depressive symptoms fell from 39% at intake to 22% at five years. In terms of a combination of symptoms and readmissions there was a good outcome in 50% of men and 65% of women, a trend comparable to that found in the whole cohort. For the whole cohort a combination of the number of symptoms and admissions disclosed a good outcome for 48%. The mean total duration of readmissions during the five years for men was 76 weeks and for women 27 weeks. Depressive symptoms were present in 38% at intake and 21% after 5 years. An overall rating of social functioning at 5 years showed no more than mild impairment for 47% of men and 74% of women, although individual items were more impaired. However, 38% of the group showed no more than mild impairment in any aspect of social functioning rated. Clinical and social outcome were, in general, closely correlated. The difference in outcome between men and women and the relations between clinical and social outcome are discussed. By means of an application of measures of association between independent and dependent variables to the onset data the clinical and social categories of pathology and impairment at 5 years were forecast.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2798648     DOI: 10.1017/s026418010000059x

Source DB:  PubMed          Journal:  Psychol Med Monogr Suppl        ISSN: 0264-1801


  38 in total

1.  Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment.

Authors:  Ian R H Falloon; Isabel Montero; Mehmet Sungur; Antonino Mastroeni; Ulf Malm; Marina Economou; Rolf Grawe; Judit Harangozo; Masafumi Mizuno; Masaaki Murakami; Bert Hager; Tilo Held; Franco Veltro; Robyn Gedye
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

Review 2.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

Review 3.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 4.  The ESSEN study of childhood-onset schizophrenia: selected results.

Authors:  C Eggers; D Bunk; G Volberg; B Röpcke
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

5.  Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.

Authors:  J F Guest; R F Cookson
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

6.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

7.  First-contact rate for schizophrenia in community psychiatric care. Consideration of the oestrogen hypothesis.

Authors:  R K Salokangas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

8.  Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study.

Authors:  Bernadette A Cullen; Katrina Rodriguez; William W Eaton; Ramin Mojtabai; Tara Von Mach; Michele L Ybarra
Journal:  Psychiatry Res       Date:  2020-07-29       Impact factor: 3.222

9.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

10.  The abilities of improved schizophrenia patients to work and live independently in the community: a 10-year long-term outcome study from Mumbai, India.

Authors:  Amresh Kumar Srivastava; Larry Stitt; Meghana Thakar; Nilesh Shah; Gurusamy Chinnasamy
Journal:  Ann Gen Psychiatry       Date:  2009-10-13       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.